Development of an LC-MS/MS-Based Analytical Method, In Vitro Characterization, and Pharmacokinetic Study of Rafoxanide Nanosuspension in Sheep
Animals · 31.03.2026 · 16 (7) · 1065
DOI: 10.3390/ani16071065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animals, online erschienen am 31.03.2026. Verfasst von Kairui Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Department of Science and Technology of Gansu Province, Chinese Academy of Agricultural Sciences.
Abstract (Originalsprache)
This study aimed to establish a more sensitive and reliable quantitative method for determining rafoxanide (RFX) in ovine plasma. The method was applied in an 84-day long-term comparative pharmacokinetic trial to evaluate the performance of a rafoxanide nanosuspension (RFX-NS) versus its conventional suspension (RFX-S) in sheep. Characterization of the two formulations revealed the following results: RFX-NS had an average particle size of 484.93 ± 43.11 nm, a uniform size distribution (PDI 0.06 ± 0.07), and a Zeta potential of −43.59 ± 0.67 mV, which were significantly superior to those of RFX-S (particle size 2379.67 ± 121.71 nm, PDI 0.93 ± 0.10, Zeta potential −38.10 ± 0.55 mV), demonstrating excellent physical stability. In vitro dissolution tests indicated a higher dissolution rate for RFX-NS (97.6% at 60 min). By integrating formulation characterization, in vitro dissolution assessment, and pharmacokinetic studies, this research provided a comprehensive analysis of the differences between the two formulations. Pharmacokinetic results showed that, compared to RFX-S, RFX-NS had a significantly reduced apparent volume of distribution (Vz/F: 856.02 ± 274.00 vs. 1404.17 ± 285.1 mL/kg, p < 0.01), a shorter elimination half-life (t1/2: 4.05 ± 1.18 vs. 5.32 ± 0.94 days, p < 0.05), and a relative bioavailability of 128.98%. These findings suggest that RFX-NS is an improved novel formulation superior to the conventional suspension, as it enhances drug efficacy and efficiency by improving drug dissolution and absorption.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.
- Key Laboratory of Veterinary Pharmaceutical Development, Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Ministry of Agriculture and Rural Affairs, Lanzhou 730050, C…
ORCID-Profile: Kairui Sun, Yaxin Zhou, Guonian Dai, Ligang Yuan, Jiyu Zhang
Förderung
- Lanzhou Institute of Husbandry and Pharmaceutical Sciences
- Department of Science and Technology of Gansu Province
- Chinese Academy of Agricultural Sciences
Zitieren
APA
Sun, K., Li, B., Cheng, F., Zhou, Y., Dai, G., Li, H., Yuan, L., & Zhang, J. (2026). Development of an LC-MS/MS-Based Analytical Method, In Vitro Characterization, and Pharmacokinetic Study of Rafoxanide Nanosuspension in Sheep. Animals, 16(7), 1065. https://doi.org/10.3390/ani16071065
Vancouver
Sun K, Li B, Cheng F, Zhou Y, Dai G, Li H, et al. Development of an LC-MS/MS-Based Analytical Method, In Vitro Characterization, and Pharmacokinetic Study of Rafoxanide Nanosuspension in Sheep. Animals. 2026;16(7):1065. doi:10.3390/ani16071065
BibTeX
@article{Sun2026,
author = {Sun, Kairui and Li, Bing and Cheng, Fusheng and Zhou, Yaxin and Dai, Guonian and Li, Haiquan and Yuan, Ligang and Zhang, Jiyu},
title = {Development of an LC-MS/MS-Based Analytical Method, In Vitro Characterization, and Pharmacokinetic Study of Rafoxanide Nanosuspension in Sheep},
journal = {Animals},
year = {2026},
volume = {16},
number = {7},
pages = {1065},
doi = {10.3390/ani16071065}
}
EUVIMED